1029521-30-9
Chemical Structure
NVP CXCR2 20
- CAS No.: 1029521-30-9
- Formula:C15H11F2N3OS
- Molecular Weight:319.33
IUPAC Name: 6-cyclopropyl-2-((2,3-difluorobenzyl)thio)-4-oxo-1,4-dihydropyrimidine-5-carbonitrile
InChIKey: PHHZYKZFEBRXAL-UHFFFAOYSA-N
SMILES: N#CC=1C(=O)N=C(SCC=2C=CC=C(F)C2F)NC1C3CC3
Biological Activity: NVP CXCR2 20 is a selective CXCR2 inhibitor with analgesic and antinociceptive activities. NVP CXCR2 20 selectively blocks CXCR2 signaling and attenuates mechanical and thermal hypersensitivity in rat chronic constriction injury (CCI) models. NVP CXCR2 20 inhibits CXCL3-induced hypersensitivity in naive mice and reduces elevated CXCL3 protein levels in the spinal cord and dorsal root ganglia (DRG) of CCI-exposed rats. NVP CXCR2 20 can be used for the research of neuropathic pain and chronic obstructive pulmonary disease (COPD)[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
NVP CXCR2 20 | NVP CXCR2 20 is a selective CXCR2 inhibitor with analgesic and antinociceptive activities. NVP CXCR2 20 selectively blocks CXCR2 signaling and attenuates mechanical and thermal hypersensitivity in rat chronic constriction injury (CCI) models. NVP CXCR2 20 inhibits CXCL3-induced hypersensitivity in naive mice and reduces elevated CXCL3 protein levels in the spinal cord and dorsal root ganglia (DRG) of CCI-exposed rats. NVP CXCR2 20 can be used for the research of neuropathic pain and chronic obstructive pulmonary disease (COPD). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Piotrowska A, et al. Pharmacological Blockade of Spinal CXCL3/CXCR2 Signaling by NVP CXCR2 20, a Selective CXCR2 Antagonist, Reduces Neuropathic Pain Following Peripheral Nerve Injury. Front Immunol. 2019;10:2198. Published 2019 Sep 26. [Content Brief]
- [2]. PRESS, Neil John et al. Pyrimidines and their use as cxcr2 receptor antagonists. WO 2008/061740 A1. World Intellectual Property Organization International Bureau. 29 May 2008.
- [3]. Porter DW, et al. The discovery of potent, orally bioavailable pyrimidine-5-carbonitrile-6-alkyl CXCR2 receptor antagonists. Bioorg Med Chem Lett. 2014;24(15):3285-3290. [Content Brief]
Keywords
